Home > Market Research > Prescription Medicines > Cardiovascular Medicine: Diagnostics, Drugs and Devices

Table of Contents

Market Study
Published: November 2007
Pages: 215
Tables: 91
From: GBP 3031.25   Buy Now!
Research from: Business Communications Company Inc.
Sector: Prescription Medicines

REPORT HIGHLIGHTS
The global market for cardiovascular diagnostics and therapy increased from $111 billion in 2006 to an estimated $119.8 billion in 2007. It should reach $192.4 billion through 2012, a compound annual growth rate (CAGR) of 9.9%.
The cardiovascular diagnostics market represents one of the largest sectors in the diagnostics industry chiefly due to the high prevalence rate of and mortality from cardiovascular disease.
Of the cardiovascular diagnostics, devices and drugs markets, the drugs market is the largest, worth an estimated $82.4 billion in 2007 and expected to reach $121.6 billion in 2012.

INTRODUCTION
This market research report is an update of BCCs original report on the topic, published in 2001. BCC's goal in conducting this study is to provide an overview of the current and potential aspects of the global market for cardiovascular drugs, devices, and diagnostics in the pharmaceutical and biotechnology industries. The report determines the market size, market leaders, and factors affecting the market of cardiovascular drugs, devices, and diagnostics.
The overview of types of cardiovascular diseases and their prevalence is examined along with sales figures over the 5-year period from 2007 to 2012. Companies selling drugs, devices, and diagnostics are profiled; the factors affecting markets for these products, and how those markets are likely to change, are analyzed. Revenues have been broken down by the type of drug products, devices implanted, and diagnoses performed.
Our key objective is to present a comprehensive analysis of the current market and the future direction of cardiovascular drugs, devices, and diagnostics, with an emphasis on newer products.
SCOPE OF STUDY
This report contains:
Descriptions of various types of cardiovascular diagnostics such as in vitro tests and in vivo imaging techniques, devices such as drug eluting stents, and drugs such as Pfizers blockbuster Lipitor
The current market status of cardiovascular diagnostics, devices and drugs, along with trends and forecasts for growth over the next 5 years
Technological issues including the latest developments and a thorough patent analysis
Analysis of the cardiovascular diagnostics, devices and drugs industry, both from a market and application perspective
Information about the major players in each market, including Medtronic and Boston Scientific in devices, Sanofi-Aventis and BMS in drugs, and Abbott in devices.
INFORMATION SOURCES
A comprehensive literature search was conducted. The literature included technical newsletters and journals, as well as many other sources. The data was collected through interviews and correspondence with various pharmaceutical/biotechnical experts. Projections were based on estimates such as the current number of end users, potential end users, likely unit prices, rates of consumption, and market trends.
BCC surveyed many companies to obtain data for this study. Included were manufacturers and end users of the pharmaceutical drugs through contract manufacturing/research. Data were gathered from the industries; spoke with officials or physicians of these industries; and consulted newsletters, company literature, product literature, a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were done. In addition, data were compiled data from current financial and trade information and government sources.

Top of Page

Table of Contents

INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
INTENDED AUDIENCE
SCOPE OF REPORT
INFORMATION SOURCES
ANALYST’S CREDENTIALS
RELATED REPORTS FROM BCC RESEARCH
BCC ONLINE SERVICES
DISCLAIMER
SUMMARY
THE CARDIOVASCULAR DIAGNOSTIC, DRUG, AND DEVICE MARKETS
SUMMARY TABLE WORLDWIDE REVENUE OF CARDIOVASCULAR DIAGNOSTICS, DRUGS, AND DEVICES, THROUGH 2012 ($ BILLIONS)
SUMMARY FIGURE WORLDWIDE REVENUE OF CARDIOVASCULAR DIAGNOSTICS, DRUGS, AND DEVICES, 2005-2012 ($ BILLIONS)
OVERVIEW
WHAT IS CARDIOVASCULAR (CV) DISEASE?
CAUSES OF CARDIOVASCULAR DISEASE
CAUSES OF CARDIOVASCULAR DISEASE (CONTINUED)
CARDIOVASCULAR DIAGNOSTICS
CARDIOVASCULAR MEDICINE
CARDIOVASCULAR DEVICES
CARDIOVASCULAR DISEASES
DISEASES OF THE HEART (CARDIO) AND DISEASES OF THE
BLOOD VESSELS (VASCULAR)
DISEASES OF THE HEART
Coronary Artery Disease (CAD)
Coronary Heart Disease (CHD)
Cardiomyopathy
Valvular Heart Disease
Pericardial Disease
Congenital Heart Disease
Heart Failure
DISEASE OF BLOOD VESSELS
Arteriosclerosis and Atherosclerosis
High Blood Pressure
Stroke
Aneurysm
Peripheral Arterial Disease and Claudication (PAD)
Vasculitis
Venous Incompetence
Venous Thrombosis
Varicose Veins
Lymphedema
EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE
Global Distribution Pattern in 2004
Age
Gender
Role of Risk Factors
Risk Factors
Psychological and Social Factors
Prevention of Cardiovascular Disease
PREVALANCE OF CARDIOVASCULAR DISEASES
MAJOR CAUSE OF DEATH
THE EPIDEMIOLOGICAL TRANSITION
PREVALENCE OF HEART DISEASE IN VARIOUS
CATEGORIES
Age
Gender
Race/ Ethnicity
Education
TABLE 1 PREVALENCE OF STROKE, MYOCARDIAL INFARCTION, AND ANGINA PECTORIS BY VARIOUS CATEGORIES, 2005
FIGURE 1 PREVALENCE OF STROKE, MYOCARDIAL INFARCTION, AND ANGINA PECTORIS BY AGE GROUP, 2005 (%)
FIGURE 2 PREVALENCE OF STROKE, MYOCARDIAL INFARCTION, AND ANGINA PECTORIS BY GENDER, 2005 (%)
FIGURE 3 PREVALENCE OF STROKE, MYOCARDIAL INFARCTION, AND ANGINA PECTORIS BY RACE/ETHINICITY, 2005 (%)
FIGURE 4 PREVALENCE OF STROKE, MYOCARDIAL INFARCTION, AND ANGINA PECTORIS BY EDUCATION 2005 (%)
PREVALENCE OF CARDIOVASCULAR DISEASES IN THE U.S.
TABLE 2 PREVALENCE OF CARDIOVASCULAR DISEASES IN U.S., 2005 (MILLION PEOPLE)
FIGURE 5 PREVALENCE OF CARDIOVASCULAR DISEASES IN THE U.S., 2005 (MILLION PEOPLE)
COST OF CARDIOVASCULAR DISEASES IN THE U.S.
TABLE 3 COST OF CARDIOVASCULAR DISEASES IN U.S. THROUGH 2012 ($ BILLIONS)
FIGURE 6 COST OF CARDIOVASCULAR DISEASES IN THE U.S., 2005-2012 ($ BILLIONS)
PREVALENCE AND COST OF CARDIOVASCULAR
DISEASES IN EUROPE
MORTALITY DUE TO CARDIOVASCULAR DISEASES U.S
TABLE 4 MORTALITY DUE TO CARDIOVASCULAR DISEASES IN THE U.S., 2005 (%)
TABLE 4 (CONTINUED)
FIGURE 7 MORTALITY DUE TO CARDIOVASCULAR DISEASES IN THE U.S. 2005 (%)
Europe
TABLE 5 MORTALITY DUE TO CARDIOVASCULAR DISEASES IN EUROPE, 2005 (%)
FIGURE 8 MORTALITY DUE TO CARDIOVASCULAR DISEASES IN THE U.S., 2005 (%)
REGULATORY ISSUES
CARDIOVASCULAR DRUGS APPROVED BY FDA
TABLE 6 CARDIOVASCULAR DRUGS APPROVED BY FDA, 2002-2007*
FIGURE 9 CARDIOVASCULAR DRUGS APPROVED BY FDA, 2002-2007*
CARDIOVASCULAR DEVICES APPROVED BY THE FDA
TABLE 7 CARDIOVASCULAR DEVICES APPROVED BY THE FDA, 2002-2007*
TABLE 7 (CONTINUED)
TABLE 7 (CONTINUED)
FIGURE 10 CARDIOVASCULAR DEVICES APPROVED BY THE FDA 2002-2007*
CARDIOVASCULAR DRUGS RECALLED BY FDA
TABLE 8 CARDIOVASCULAR DRUGS RECALLED BY THE FDA, 2002-2007*
CARDIOVASCULAR DEVICES RECALLED BY FDA
TABLE 9 CARDIOVASCULAR DEVICES RECALLED BY THE FDA, 2002-2007*
TABLE 9 (CONTINUED)
FIGURE 11 CARDIOVASCULAR DEVICES RECALLED BY FDA, 2002-2007*
FIGURE 11 (CONTINUED)
NEW DRUG APPLICATIONS
NEW DRUG APPLICATIONS (CONTINUED)
NEW DRUG APPLICATIONS (CONTINUED)
CARDIOVASCULAR DIAGNOSTICS
DIAGNOSTICS DEFINITION
IN VITRO DIAGNOSTIC
BIOMARKERS
Aspartate Aminotransferase (AST/GOT)
Lactate Dehydrogenase and its Isoenzyme LD
Creatine Kinase (CK) and its Isoenzyme MB
Myoglobin
Cardiac Troponins
Reasons behind the Replacement of CKMB with
Troponins
Myoglobin/Carbonic Anhydrase III Ratio
Glycogen Phosphorylase Isoenzyme BB
Heart Type Fatty Acid Binding Protein
COMPARISON BETWEEN CTNT AND CTNL
Natriuretic Peptides as Cardiac Biomarkers
TABLE 10 NT-PROBNP IN ACUTE SITUATIONS
TABLE 11 NT-PROBNP IN PRIMARY CARE SETTING
POINT-OF-CARE TESTING
NEED FOR THE POCT
TABLE 12 ADVANTAGES OF POINT OF CARE TESTING
TABLE 13 DISADVANTAGES OF POINT OF CARE TESTING
Past, Present, and Future of Point-of-Care Testing
Past
Present
Future
DETERMINING WHETHER TO USE POC CARDIAC
TESTING IN THE ED
Considerations of Turnaround Times
The Importance of Quantitative Results
Concerns about Standardization
VENUES FOR POC TESTING
TABLE 14 VENUES FOR POC TESTING
IN VIVO DIAGNOSTICS
ECHOCARDIOGRAPHY
Need of the Echocardiography
TABLE 15 TYPES OF ECHOCARDIOGRAMS
ULTRASOUND
TABLE 16 TYPES OF DOPPLER ULTRASOUND
Advantages of Ultrasound
MRI
Need of MRI Scan
POSITRON EMISSION TOMOGRAPHY
COMPUTED TOMOGRAPHY
Electron-Beam Computed Tomography (EBCT or
Ultrafast CT)
Electron-Beam Computed (Continued)
CARDIOVASCULAR THERAPY
CARDIOVASCULAR DRUGS
ANTI-ANGINAL AGENTS
TABLE 17 COMMONLY USED ANTI-ANGINAL AGENTS
ANTI-ARRHYTHMIC AGENTS
TABLE 18 COMMONLY USED ANTI-ARRHYTHMIC AGENTS
ANTI-HYPERTENSIVE DRUGS
TABLE 19 COMMONLY USED ANTI-HYPERTENSIVE AGENTS
ANTI-THROMBOTIC AGENTS
BLOOD LIPID LOWERING AGENTS
TABLE 20 COMMONLY USED BLOOD LIPID LOWERING AGENTS
DRUGS USED TO TREAT CONGESTIVE HEART FAILURE
TABLE 21 COMMONLY USED DRUGS TO TREAT CONGESTIVE HEART FAILURE
CARDIOVASCULAR DEVICES
PACEMAKERS
TABLE 22 PACEMAKERS
Defibrillators
Manual External Defibrillators
Manual Internal Defibrillator
Automated External Defibrillator
Semi-automated External Defibrillator
Implantable Cardioverter Defibrillator
Drug-Eluting Stents (DES)
Catheters
Valves
Mechanical Heart Valve
Biological Heart Valve
Ventricular Assist Device
Guidewires
Artificial Heart
CARDIAC RESYNCHRONIZATION THERAPY
Cardiac Resynchronization Therapy
Cardiac Resynchronization Therapy Devices
Difference between Biventricular Pacemaker and
Standard Pacemaker
Use of CRT
Benefits of CRT
Potential Risks with Biventricular Pacemakers
INDUSTRY STRUCTURE
CARDIOVASCULAR DIAGNOSTICS
CARDIAC BIOMARKERS
TABLE 23 PRESENT CARDIAC MARKER TESTING
Market Shares for Companies Providing Biomarker Tests
TABLE 24 MARKET SHARE OF COMPANIES PROVIDING BIOMARKER TESTS, 2006 (%)
FIGURE 12 MARKET SHARE OF COMPANIES PROVIDING BIOMARKER TESTS, 2006 (%)
Effect of POCT on the Growth of Cardiac Biomarker
Testing in Laboratory
POINT OF TESTING FOR CARDIAC BIOMARKERS
TABLE 25 PRESENT POINT-OF-CARE TESTING FOR CARDIAC BIOMARKERS
Market Shares for Companies Providing Biomarker Tests
TABLE 26 MARKET SHARE OF COMPANIES PROVIDING POINT-OFCARE TESTING FOR CARDIAC BIOMARKERS, 2006 (%)
FIGURE 13 MARKET SHARE OF COMPANIES PROVIDING POINT-OF CARE TESTING FOR CARDIAC BIOMARKERS, 2006 (%)
Factors Influencing the Growth of Point-of-Care Testing
Challenges for the Manufacturers
IN-VIVO DIAGNOSTICS
TABLE 27 PRESENT IMAGING SYSTEMS FOR IN-VIVO DIAGNOSIS
Market Shares for Companies Providing In-Vivo
Diagnostics
TABLE 28 MARKET SHARE OF COMPANIES PROVIDING IN-VIVO DIAGNOSTICS, 2006 (%)
FIGURE 14 MARKET SHARE OF COMPANIES PROVIDING IN-VIVO DIAGNOSTICS, 2006 (%)
Factors Affecting the Growth of Cardiac Imaging or In
vivo Diagnostics
CARDIOVASCULAR DRUGS
ANTI-ANGINAL AGENTS
TABLE 29 GLOBAL MARKET LEADERS OF ANTI-ANGINAL AGENTS
Market Shares for Anti-anginal Agents
TABLE 30 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-ANGINAL AGENTS, 2006 (%)
FIGURE 15 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-ANGINAL AGENTS, 2006 (%)
ANTI-ARRYHTHMIC AGENTS
TABLE 31 GLOBAL MARKET LEADERS OF ANTI-ARRHYTHMIC AGENTS
Market Shares for Anti-arrhythmic Agents
TABLE 32 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-ARRHYTHMIC AGENTS, 2006 (%)
FIGURE 16 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-ARRHYTHMIC AGENTS, 2006 (%)
ANTI-HYPERTENSIVE AGENTS
TABLE 33 GLOBAL MARKET LEADERS OF ANTI-HYPERTENSIVE AGENTS
Market Shares for Anti-hypertensive Agents
TABLE 34 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-HYPERTENSIVE AGENTS, 2006 (%)
FIGURE 17 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-HYPERTENSIVE AGENTS, 2006 (%)
ANTI-THROMBOTIC AGENTS
TABLE 35 GLOBAL MARKET LEADERS OF ANTI-THROMBOTIC AGENTS
Market Shares for Anti-thrombotic Agents
TABLE 36 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-THROMBOTIC AGENTS, 2006 (%)
FIGURE 18 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-THROMBOTIC AGENTS, 2006 (%)
BLOOD LIPID LOWERING AGENTS
TABLE 37 GLOBAL MARKET LEADERS OF BLOOD LIPID LOWERING AGENTS
Market Shares for Blood Lipid Lowering Agents
TABLE 38 MARKET SHARE OF COMPANIES MANUFACTURING BLOOD LIPID LOWERING AGENTS, 2006 (%)
FIGURE 19 MARKET SHARE OF COMPANIES MANUFACTURING BLOOD LIPID LOWERING AGENTS, 2006 (%)
DRUGS TREATING CONGESTIVE HEART FAILURE
TABLE 39 GLOBAL MARKET LEADERS OF DRUGS TREATING CONGESTIVE HEART FAILURE
Market Shares for Drugs Treating Congestive Heart
Failure
TABLE 40 MARKET SHARE OF COMPANIES MANUFACTURING DRUGS TREATING CONGESTIVE HEART FAILURE, 2006 (%)
TABLE 40 (CONTINUED)
FIGURE 20 MARKET SHARE OF COMPANIES MANUFACTURING DRUGS TREATING CONGESTIVE HEART FAILURE, 2006 (%)
FACTORS AFFECTING THE SALES OF CARDIOVASCULAR
DRUGS
Price Control/Price pressure
Expiration of Patents
MAJOR FACTORS FOR FUTURE GROWTH
Life Expectancy
Access of Senior Citizens to Prescription Drugs
Patent Protection
Drugs Portfolio Management
Significant Potential of Developing Countries
CARDIOVASCULAR DEVICES
PACEMAKERS
TABLE 41 GLOBAL MARKET LEADERS OF MANUFACTURERS OF PACEMAKERS
Market Shares of Companies Manufacturing Pacemakers
TABLE 42 MARKET SHARE OF COMPANIES MANUFACTURING PACEMAKERS, 2006 (%)
FIGURE 21 MARKET SHARE OF COMPANIES MANUFACTURING PACEMAKERS, 2006 (%)
CARDIOVERTER DEFIBRILLATORS
TABLE 43 GLOBAL MARKET LEADERS OF MANUFACTURERS OF CONVENTIONAL CARDIOVERTER DEFIBRILLATORS
TABLE 44 GLOBAL MARKET LEADERS OF MANUFACTURERS OF CRT-DEFIBRILLATORS
Market Shares of Companies Manufacturing
Conventional Cardioverter Defibrillators
TABLE 45 MARKET SHARE OF COMPANIES MANUFACTURING CONVENTIONAL CARDIOVERTER DEFIBRILLATORS, 2006 (%)
FIGURE 22 MARKET SHARE OF COMPANIES MANUFACTURING CONVENTIONAL CARDIOVERTER DEFIBRILLATORS, 2006 (%)
Market Shares of Companies Manufacturing CRTDefibrillators
TABLE 46 MARKET SHARE OF COMPANIES MANUFACTURING CRT-DEFIBRILLATORS, 2006 (%)
FIGURE 23 MARKET SHARE OF COMPANIES MANUFACTURING CRT-DEFIBRILLATORS, 2006 (%)
DRUG ELUTING STENTS
TABLE 47 GLOBAL MARKET LEADERS OF MANUFACTURERS OF DRUG ELUTING STENTS
Market Shares of Companies Manufacturing Drug
Eluting Stents
TABLE 48 MARKET SHARE OF COMPANIES MANUFACTURING DRUG ELUTING STENTS, 2006 (%)
FIGURE 24 MARKET SHARE OF COMPANIES MANUFACTURING DRUG ELUTING STENTS, 2006 (%)
CATHETERS
TABLE 49 GLOBAL MARKET LEADERS OF MANUFACTURERS OF CATHETERS
TABLE 49 (CONTINUED)
Market Shares of Companies Manufacturing Catheters
TABLE 50 MARKET SHARE OF COMPANIES MANUFACTURING CATHETERS, 2006 (%)
FIGURE 25 MARKET SHARE OF COMPANIES MANUFACTURING CATHETERS, 2006 (%)
HEART VALVES
TABLE 51 GLOBAL MARKET LEADERS OF MANUFACTURERS OF HEART VALVES
Market Shares of Companies Manufacturing Heart
Valves
TABLE 52 MARKET SHARE OF COMPANIES MANUFACTURING HEART VALVES, 2006 (%)
FIGURE 26 MARKET SHARE OF COMPANIES MANUFACTURING HEART VALVES, 2006 (%)
VENTRICULAR ASSIST DEVICE
TABLE 53 GLOBAL MARKET LEADERS OF MANUFACTURERS OF VENTRICULAR ASSIST DEVICES
Market Shares of Companies Manufacturing Ventricular
Assist Devices
TABLE 54 MARKET SHARE OF COMPANIES MANUFACTURING VENTRICULAR ASSIST DEVICES, 2006 (%)
FIGURE 27 MARKET SHARE OF COMPANIES MANUFACTURING VENTRICULAR ASSIST DEVICES, 2006 (%)
GUIDE WIRES
TABLE 55 GLOBAL MARKET LEADERS OF MANUFACTURERS OF GUIDE WIRES
Market Shares of Companies Manufacturing Guidewires
TABLE 56 MARKET SHARE OF COMPANIES MANUFACTURING GUIDEWIRES, 2006 (%)
FIGURE 28 MARKET SHARE OF COMPANIES MANUFACTURING GUIDEWIRES, 2006 (%)
FACTORS AFFECTING THE SALES OF CARDIOVASCULAR
DEVICES
Aging Baby-Boomers
Regulation
Competitive Landscape of Technology
Shortening of Patent Lives
Business Taxes
MARKET ANALYSIS OF CARDIOVASCULAR DIAGNOSTICS
CARDIAC BIOMARKERS
TABLE 57 GLOBAL SALES OF CARDIAC BIOMARKERS, THROUGH 2012 ($ MILLIONS)
FIGURE 29 GLOBAL SALES OF CARDIAC BIOMARKERS, 2005-2012 ($ MILLIONS)
CARDIAC MARKER TESTING BY TYPE
TABLE 58 ESTIMATED WORLDWIDE MARKET FOR CARDIAC MARKER TESTING BY TYPE, THROUGH 2012 ($ MILLIONS)
FIGURE 30 GLOBAL SALES OF CARDIAC BIOMARKERS, BY TYPE, 2005-2012 ($ MILLIONS)
POINT-OF-CARE TESTING
TABLE 59 GLOBAL SALES OF POINT-OF-CARE TESTING, THROUGH 2012 ($ MILLIONS)
FIGURE 31 GLOBAL SALES OF POINT-OF-CARE TESTING, 2005-2012 ($ MILLIONS)
IN VIVO DIAGNOSTICS
In Vivo Diagnostics (Continued)
TABLE 60 GLOBAL SALES OF IN-VIVO DIAGNOSTICS, THROUGH 2012 ($ MILLIONS)
FIGURE 32 GLOBAL SALES OF IN VIVO DIAGNOSTICS. 2005-2012 ($ MILLIONS)
TOTAL MARKET SHARES OF CARDIOVASCULAR
DIAGNOSTICS WORLDWIDE
TABLE 61 WORLDWIDE MARKET SHARE OF CARDIOVASCULAR DIAGNOSTICS, 2006 (%)
FIGURE 33 WORLDWIDE MARKET SHARE OF CARDIOVASCULAR DIAGNOSTICS, 2006 (%)
MARKET ANALYSIS OF CARDIOVASCULAR DRUGS
ANTI-ANGINAL AGENTS
TABLE 62 GLOBAL SALES OF ANTI-ANGINAL DRUGS, THROUGH 2012 ($ BILLIONS)
FIGURE 34 GLOBAL SALES OF ANTI-ANGINAL DRUGS, 2005-2012 ($ BILLIONS)
ANTI-ARRHYTHMIC AGENTS
TABLE 63 GLOBAL SALES OF ANTI-ARRHYTHMIC DRUGS, THROUGH 2012 ($ BILLIONS)
FIGURE 35 GLOBAL SALES OF ANTI-ARRHYTHMIC DRUGS, 2005-2012 ($ BILLIONS)
ANTI-HYPERTENSIVE AGENTS
TABLE 64 GLOBAL SALES OF ANTI-HYPERTENSIVE DRUGS, THROUGH 2012 ($ BILLIONS)
FIGURE 36 GLOBAL SALES OF ANTI-HYPERTENSIVE DRUGS, 2005-2012 ($ BILLIONS)
ANTI-THROMBOTIC AGENTS
TABLE 65 GLOBAL SALES OF ANTI-THROMBOTIC DRUGS, THROUGH 2012 ($ BILLIONS)
FIGURE 37 GLOBAL SALES OF ANTI-THROMBOTIC DRUGS, 2005-2012 ($ BILLIONS)
BLOOD LIPID LOWERING AGENTS
TABLE 66 GLOBAL SALES OF BLOOD LIPID LOWERING DRUGS, THROUGH 2012 ($ BILLIONS)
FIGURE 38 GLOBAL SALES OF BLOOD LIPID LOWERING DRUGS, 2005-2012 ($ BILLIONS)
DRUGS USED TO TREAT CONGESTIVE HEART FAILURE
TABLE 67 GLOBAL SALES OF DRUGS USED TO TREAT CONGESTIVE HEART FAILURE, THROUGH 2012 ($ BILLIONS)
FIGURE 39 GLOBAL SALES OF DRUGS USED TO TREAT CONGESTIVE HEART FAILURE, 2005-2012 ($ BILLIONS)
TOTAL WORLDWIDE MARKET SHARES OF CARDIOVASCULAR DRUGS
TABLE 68 MARKET SHARE OF CARDIOVASCULAR DRUGS, 2006 (%)
FIGURE 40 MARKET SHARE OF CARDIOVASCULAR DRUGS, 2006
(%)
CARDIOVASCULAR DEVICES MARKET ANALYSIS
PACEMAKERS
TABLE 69 GLOBAL SALES OF PACEMAKERS, THROUGH 2012 ($ MILLIONS)
FIGURE 41 GLOBAL SALES OF PACEMAKERS, 2005-2012 ($ MILLIONS)
IMPLANTABLE CARDIOVERTER DEFIBRILLATORS
TABLE 70 GLOBAL SALES OF CONVENTIONAL IMPLANTABLE CARDIOVERTER DEVICES, THROUGH 2012 ($ MILLIONS)
FIGURE 42 GLOBAL SALES OF IMPLANTABLE CARDIOVERTER DEVICES, 2005-2012 ($ MILLIONS)
TABLE 71 GLOBAL SALES OF CRT-DEFIBRILLATORS, THROUGH 2012 ($ MILLIONS)
FIGURE 43 GLOBAL SALES OF IMPLANTABLE CRTDEFIBRILLATORS, 2005-2012 ($ MILLIONS)
DRUG ELUTING STENTS (DES) AND GRAFTS
Drug Eluting Stents (DES) and Grafts (Continued)
TABLE 72 GLOBAL SALES OF DRUG ELUTING STENTS AND GRAFTS, THROUGH 2012 ($ MILLIONS)
FIGURE 44 GLOBAL SALES OF DRUG ELUTING STENTS AND GRAFTS, 2005-2012 ($ MILLIONS)
CATHETERS
TABLE 73 GLOBAL SALES OF CATHETERS, THROUGH 2012 ($ MILLIONS)
FIGURE 45 GLOBAL SALES OF CATHETERS, 2005-2012 ($ MILLIONS)
HEART VALVES
TABLE 74 GLOBAL SALES OF HEART VALVES, THROUGH 2012 ($ MILLIONS)
FIGURE 46 GLOBAL SALES OF HEART VALVES, THROUGH 2012 ($ MILLIONS)
VENTRICULAR ASSIST DEVICES
TABLE 75 GLOBAL SALES OF VENTRICULAR ASSIST DEVICES, THROUGH 2012 ($ MILLIONS)
FIGURE 47 GLOBAL SALES OF VENTRICULAR ASSIST DEVICES, 2005-2012 ($ MILLIONS)
GUIDEWIRES
TABLE 76 GLOBAL SALES OF GUIDEWIRES, THROUGH 2012 ($ MILLIONS)
FIGURE 48 GLOBAL SALES OF GUIDEWIRES, 2005-2012 ($ MILLIONS)
ARTIFICIAL HEART
TOTAL MARKET SHARES OF CARDIOVASCULAR DEVICES WORLDWIDE
TABLE 77 MARKET SHARE OF CARDIOVASCULAR DEVICES, 2006 (%)
FIGURE 49 MARKET SHARE OF CARDIOVASCULAR DEVICES, 2006 (%)
NEW DEVELOPMENTS/TECHNOLOGICAL INNOVATIONS
DIAGNOSTICS
SIEMENS MEDICAL SOLUTIONS
NEUROSONIX LTD
UNIVERSITY HOSPITAL MANNHEIM AND OSPEDALI
RIUNITI DI BERGAMO
SORIN
PHILIPS
TOPSPIN MEDICAL
SONOSITE, INC.
DATASCOPE CORPORATION
RESPONSE BIOMEDICAL
ASTRAZENECA
BMS & PFIZER
DECODE GENETICS
ENCYSIVE PHARMACEUTICALS INC.
EPIX PHARMACEUTICALS, INC
LEXICON PHARMACEUTICALS
MERCK & COMPANY
MOMENTA PHARMACEUTICALS, INC
NILE THERAPEUTICS, INC
PHARMACOPEIA
SANOFI-AVENTIS
TAKEDA PHARMACEUTICAL
UNIVERSITY OF NORTH CAROLINA
DEVICES
ABBOTT
ABIOMED, INC
ATS MEDICAL
CARDIATIS
CRYOCATH TECHNOLOGIES, INC.
CRYOCOR, INC.
EDWARD LIFESCIENCES
MEDTRONIC, INC.
METHODIST DEBAKEY HEART CENTER
ST. JUDE MEDICAL, INC.
STEM CELLS AND HEART DISEASE
STEM CELLS AND HEART DISEASE (CONTINUED)
PATENT ANALYSIS
TOTAL PATENTS
PATENTS BY YEAR
TABLE 78 TOTAL NUMBER OF SIGNIFICANT PATENTS, 2005-2007
FIGURE 50 NUMBER OF PATENTS, 2005-2007
FIGURE 51 NUMBER OF PATENTS, SHARE BY YEAR, 2005-2007 (%)
PATENTS BY COUNTRY
TABLE 79 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2007
FIGURE 52 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2007
DIAGNOSTICS PATENTS
PATENTS BY YEAR
TABLE 80 PATENTS FOR DIAGNOSTICS BY YEAR, 2005-2007
FIGURE 53 PATENTS FOR DIAGNOSTICS BY YEAR, 2005-2007
PATENTS BY COUNTRY
TABLE 81 PATENTS BY COUNTRY FOR DIAGNOSTICS, 2005-2007
FIGURE 54 PATENTS BY COUNTRY FOR DIAGNOSTICS, 2005-2007
PATENTS BY COMPANY
TABLE 82 NUMBER OF PATENTS BY COMPANY FOR DIAGNOSTICS
TABLE 82 (CONTINUED)
FIGURE 55 TOTAL NUMBER OF PATENTS BY COMPANY FOR DIAGNOSTICS, 2005-2007
PATENTS BY ASSIGNEE
TABLE 83 NUMBER OF PATENTS BY ASSIGNEE FOR DIAGNOSTICS, 2005-2007
FIGURE 56 NUMBER OF PATENTS BY ASSIGNEE FOR DIAGNOSTICS, 2005-2007
DRUG PATENTS
PATENTS BY COUNTRY
TABLE 84 PATENTS BY COUNTRY FOR DRUGS, 2005-2007
FIGURE 57 PATENTS BY COUNTRY FOR DRUGS, 2005-2007
PATENTS BY COMPANY
TABLE 85 NUMBER OF PATENTS BY COMPANY FOR DRUGS, 2005-2007
TABLE 85 (CONTINUED)
FIGURE 58 TOTAL NUMBER OF PATENTS BY COMPANY FOR DRUGS, 2005-2007
Patents by Assignee
TABLE 86 NUMBER OF PATENTS BY ASSIGNEE FOR DEVICES, 2005-2007
FIGURE 59 NUMBER OF PATENTS BY ASSIGNEE FOR DRUGS, 2005-2007
DEVICE PATENTS
PATENTS BY YEAR
TABLE 87 PATENTS FOR DEVICES BY YEAR, 2005-2007
FIGURE 60 PATENTS FOR DEVICES BY YEAR, 2005-2007
PATENTS BY COUNTRY
TABLE 88 PATENTS BY COUNTRY FOR DEVICES, 2005-2007
FIGURE 61 PATENTS BY COUNTRY FOR DEVICES, 2005-2007
PATENTS BY COMPANY
TABLE 89 NUMBER OF PATENTS BY COMPANY FOR DEVICES, 2005-2007
TABLE 89 (CONTINUED)
FIGURE 62 TOTAL NUMBER OF PATENTS BY COMPANY FOR DEVICES, 2005-2007
PATENTS BY ASSIGNEE
TABLE 90 NUMBER OF PATENTS BY ASSIGNEE FOR DEVICES, 2005-2007
FIGURE 63 NUMBER OF PATENTS BY ASSIGNEE FOR DEVICES, 2005-2007
COMPANY PROFILES FOR DIAGNOSTICS
ABBOTT LABORATORIES INC
AXIS-SHIELD PLC
BAYER AG
BECKMAN COULTER INC
BIOMÉRIEUX INC
BIOSITE INCORPORATED
BIOSOUND ESAOTE INC
CAMBRIDGE HEART INC.
CHOLESTECH
COVIDIEN
DADE BEHRING INC
DELTEX MEDICAL GROUP PLC
EPIX PHARMACEUTICALS, INC.
EP MEDSYSTEMS
FONAR CORPORATION
GE HEALTHCARE
HYPERTENSION DIAGNOSTIC INC.
INVERNESS MEDICAL INNOVATIONS, INC
MALLINCKRODT
MEDISON AMERICA INC
MORTARA INSTRUMENT INC
OLYMPUS AMERICA INC.
ORTHO-CLINICAL DIAGNOSTICS, INC. (JOHNSON & JOHNSON
CO.)
PHILIPS MEDICAL SYSTEM
PREMD INC
RESPONSE BIOMEDICAL CORP.
ROCHE HOLDING
SIEMENS
SONOSITE
SONOSITE (CONTINUED)
COMPANY PROFILES FOR DRUGS
ABBOTT LABORATORIES INC
ASTRAZENECA PLC
BAYER HEALTHCARE PHARMACEUTICALS INC.
BIOVAIL CORPORATION
BOEHRINGER INGELHEIM
BRISTOL-MYERS SQUIBB COMPANY
CV THERAPEUTICS INC
HOFFMAN-LA ROCHE INC.
KRKA GROUP
LES LABORATORIES SERVIER
MERCK & CO. INC.
MERCK KGAA
NOVARTIS AG
PFIZER INC
SANOFI AVENTIS
SCHERING PLOUGH
SOLVAY S.A.
UCB
WYETH
ZENTIVA N.V.
COMPANY PROFILES FOR DEVICES
AMBU INTERNATIONAL AS
ANGIODYNAMICS INC
ASAHI INTECC CO., LTD.
ATS MEDICAL INC
BACCHUS VASCULAR
BIOHEART INC
BIOSENSOR INTERNATIONAL GROUP
BOSTON SCIENTIFIC CORPORATION
CARDIMA INC
CONOR MEDSYSTEMS, LLC
COOK GROUP
CORDIS CORPORATION (JOHNSON &JOHNSON CO.)
COREVALVE
C.R. BARD INC
CRYOCATH
CRYOCOR
DATASCOPE CORP.
EDWARD LIFESCIENCES CORP.
GOODMAN CO. LTD
HANSEN MEDICAL
HOSPIRA
JAPAN LIFELINE
MEDTRONIC
MERIT MEDICAL SYSTEM INC.
NMT MEDICAL INC.
POSSIS MEDICAL
SORIN GROUP
ST.JUDE MEDICAL
TERUMO
THORATEC
VASCULAR SOLUTIONS INC
WORLD HEART CORP
ZOLL MEDICAL INC.
APPENDIX
TABLE 91 ACRONYMS
TABLE 91 (CONTINUED)
TABLE 91 (CONTINUED)
LIST OF TABLES
SUMMARY TABLE WORLDWIDE REVENUE OF CARDIOVASCULAR DIAGNOSTICS, DRUGS, AND DEVICES, THROUGH 2012 ($ BILLIONS)
TABLE 1 PREVALENCE OF STROKE, MYOCARDIAL INFARCTION, AND ANGINA PECTORIS BY VARIOUS CATEGORIES, 2005
TABLE 2 PREVALENCE OF CARDIOVASCULAR DISEASES IN U.S., 2005 (MILLION PEOPLE)
TABLE 3 COST OF CARDIOVASCULAR DISEASES IN U.S. THROUGH 2012 ($ BILLIONS)
TABLE 4 MORTALITY DUE TO CARDIOVASCULAR DISEASES IN THE U.S., 2005 (%)
TABLE 5 MORTALITY DUE TO CARDIOVASCULAR DISEASES IN EUROPE, 2005 (%)
TABLE 6 CARDIOVASCULAR DRUGS APPROVED BY FDA, 2002-2007*
TABLE 7 CARDIOVASCULAR DEVICES APPROVED BY THE FDA, 2002-2007*
TABLE 8 CARDIOVASCULAR DRUGS RECALLED BY THE FDA, 2002-2007*
TABLE 9 CARDIOVASCULAR DEVICES RECALLED BY THE FDA, 2002-2007*
TABLE 10 NT-PROBNP IN ACUTE SITUATIONS
TABLE 11 NT-PROBNP IN PRIMARY CARE SETTING
TABLE 12 ADVANTAGES OF POINT OF CARE TESTING
TABLE 13 DISADVANTAGES OF POINT OF CARE TESTING
TABLE 14 VENUES FOR POC TESTING
TABLE 15 TYPES OF ECHOCARDIOGRAMS
TABLE 16 TYPES OF DOPPLER ULTRASOUND
TABLE 17 COMMONLY USED ANTI-ANGINAL AGENTS
TABLE 18 COMMONLY USED ANTI-ARRHYTHMIC AGENTS
TABLE 19 COMMONLY USED ANTI-HYPERTENSIVE AGENTS
TABLE 20 COMMONLY USED BLOOD LIPID LOWERING AGENTS
TABLE 21 COMMONLY USED DRUGS TO TREAT CONGESTIVE HEART FAILURE
TABLE 22 PACEMAKERS
TABLE 23 PRESENT CARDIAC MARKER TESTING
TABLE 24 MARKET SHARE OF COMPANIES PROVIDING BIOMARKER TESTS, 2006 (%)
TABLE 25 PRESENT POINT-OF-CARE TESTING FOR CARDIAC BIOMARKERS
TABLE 26 MARKET SHARE OF COMPANIES PROVIDING POINT-OFCARE TESTING FOR CARDIAC BIOMARKERS, 2006 (%)
TABLE 27 PRESENT IMAGING SYSTEMS FOR IN-VIVO DIAGNOSIS
TABLE 28 MARKET SHARE OF COMPANIES PROVIDING IN-VIVO DIAGNOSTICS, 2006 (%)
TABLE 29 GLOBAL MARKET LEADERS OF ANTI-ANGINAL AGENTS
TABLE 30 MARKET SHARE OF COMPANIES MANUFACTURING ANTIANGINAL AGENTS, 2006 (%)
TABLE 31 GLOBAL MARKET LEADERS OF ANTI-ARRHYTHMIC AGENTS
TABLE 32 MARKET SHARE OF COMPANIES MANUFACTURING ANTIARRHYTHMIC AGENTS, 2006 (%)
TABLE 33 GLOBAL MARKET LEADERS OF ANTI-HYPERTENSIVE AGENTS
TABLE 34 MARKET SHARE OF COMPANIES MANUFACTURING ANTIHYPERTENSIVE AGENTS, 2006 (%)
TABLE 35 GLOBAL MARKET LEADERS OF ANTI-THROMBOTIC AGENTS
TABLE 36 MARKET SHARE OF COMPANIES MANUFACTURING ANTITHROMBOTIC AGENTS, 2006 (%)
TABLE 37 GLOBAL MARKET LEADERS OF BLOOD LIPID LOWERING AGENTS
TABLE 38 MARKET SHARE OF COMPANIES MANUFACTURING BLOOD LIPID LOWERING AGENTS, 2006 (%)
TABLE 39 GLOBAL MARKET LEADERS OF DRUGS TREATING CONGESTIVE HEART FAILURE
TABLE 40 MARKET SHARE OF COMPANIES MANUFACTURING DRUGS TREATING CONGESTIVE HEART FAILURE, 2006 (%)
TABLE 41 GLOBAL MARKET LEADERS OF MANUFACTURERS OF PACEMAKERS
TABLE 42 MARKET SHARE OF COMPANIES MANUFACTURING PACEMAKERS, 2006 (%)
TABLE 43 GLOBAL MARKET LEADERS OF MANUFACTURERS OF CONVENTIONAL CARDIOVERTER DEFIBRILLATORS
TABLE 44 GLOBAL MARKET LEADERS OF MANUFACTURERS OF CRTDEFIBRILLATORS
TABLE 45 MARKET SHARE OF COMPANIES MANUFACTURING CONVENTIONAL CARDIOVERTER DEFIBRILLATORS, 2006 (%)
TABLE 46 MARKET SHARE OF COMPANIES MANUFACTURING CRTDEFIBRILLATORS, 2006 (%)
TABLE 47 GLOBAL MARKET LEADERS OF MANUFACTURERS OF DRUG ELUTING STENTS
TABLE 48 MARKET SHARE OF COMPANIES MANUFACTURING DRUG ELUTING STENTS, 2006 (%)
TABLE 49 GLOBAL MARKET LEADERS OF MANUFACTURERS OF CATHETERS
TABLE 50 MARKET SHARE OF COMPANIES MANUFACTURING CATHETERS, 2006 (%)
TABLE 51 GLOBAL MARKET LEADERS OF MANUFACTURERS OF HEART VALVES
TABLE 52 MARKET SHARE OF COMPANIES MANUFACTURING HEART VALVES, 2006 (%)
TABLE 53 GLOBAL MARKET LEADERS OF MANUFACTURERS OF VENTRICULAR ASSIST DEVICES
TABLE 54 MARKET SHARE OF COMPANIES MANUFACTURING VENTRICULAR ASSIST DEVICES, 2006 (%)
TABLE 55 GLOBAL MARKET LEADERS OF MANUFACTURERS OF GUIDE WIRES
TABLE 56 MARKET SHARE OF COMPANIES MANUFACTURING GUIDEWIRES, 2006 (%)
TABLE 57 GLOBAL SALES OF CARDIAC BIOMARKERS, THROUGH 2012 ($ MILLIONS)
TABLE 58 ESTIMATED WORLDWIDE MARKET FOR CARDIAC MARKER TESTING BY TYPE, THROUGH 2012 ($ MILLIONS)
TABLE 59 GLOBAL SALES OF POINT-OF-CARE TESTING, THROUGH 2012 ($ MILLIONS)
TABLE 60 GLOBAL SALES OF IN-VIVO DIAGNOSTICS, THROUGH 2012 ($ MILLIONS)
TABLE 61 WORLDWIDE MARKET SHARE OF CARDIOVASCULAR DIAGNOSTICS, 2006 (%)
TABLE 62 GLOBAL SALES OF ANTI-ANGINAL DRUGS, THROUGH 2012 ($ BILLIONS)
TABLE 63 GLOBAL SALES OF ANTI-ARRHYTHMIC DRUGS, THROUGH 2012 ($ BILLIONS)
TABLE 64 GLOBAL SALES OF ANTI-HYPERTENSIVE DRUGS, THROUGH 2012 ($ BILLIONS)
TABLE 65 GLOBAL SALES OF ANTI-THROMBOTIC DRUGS, THROUGH 2012 ($ BILLIONS)
TABLE 66 GLOBAL SALES OF BLOOD LIPID LOWERING DRUGS, THROUGH 2012 ($ BILLIONS)
TABLE 67 GLOBAL SALES OF DRUGS USED TO TREAT CONGESTIVE HEART FAILURE, THROUGH 2012 ($ BILLIONS)
TABLE 68 MARKET SHARE OF CARDIOVASCULAR DRUGS, 2006 (%)
TABLE 69 GLOBAL SALES OF PACEMAKERS, THROUGH 2012 ($ MILLIONS)
TABLE 70 GLOBAL SALES OF CONVENTIONAL IMPLANTABLE CARDIOVERTER DEVICES, THROUGH 2012 ($ MILLIONS)
TABLE 71 GLOBAL SALES OF CRT-DEFIBRILLATORS, THROUGH 2012 ($ MILLIONS)
TABLE 72 GLOBAL SALES OF DRUG ELUTING STENTS AND GRAFTS, THROUGH 2012 ($ MILLIONS)
TABLE 73 GLOBAL SALES OF CATHETERS, THROUGH 2012 ($ MILLIONS)
TABLE 74 GLOBAL SALES OF HEART VALVES, THROUGH 2012 ($ MILLIONS)
TABLE 75 GLOBAL SALES OF VENTRICULAR ASSIST DEVICES, THROUGH 2012 ($ MILLIONS)
TABLE 76 GLOBAL SALES OF GUIDEWIRES, THROUGH 2012 ($ MILLIONS)
TABLE 77 MARKET SHARE OF CARDIOVASCULAR DEVICES, 2006 (%)
TABLE 78 TOTAL NUMBER OF SIGNIFICANT PATENTS, 2005-2007
TABLE 79 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2007
TABLE 80 PATENTS FOR DIAGNOSTICS BY YEAR, 2005-2007
TABLE 81 PATENTS BY COUNTRY FOR DIAGNOSTICS, 2005-2007
TABLE 82 NUMBER OF PATENTS BY COMPANY FOR DIAGNOSTICS
TABLE 83 NUMBER OF PATENTS BY ASSIGNEE FOR DIAGNOSTICS, 2005-2007
TABLE 84 PATENTS BY COUNTRY FOR DRUGS, 2005-2007
TABLE 85 NUMBER OF PATENTS BY COMPANY FOR DRUGS, 2005-2007
TABLE 86 NUMBER OF PATENTS BY ASSIGNEE FOR DEVICES, 2005-2007
TABLE 87 PATENTS FOR DEVICES BY YEAR, 2005-2007
TABLE 88 PATENTS BY COUNTRY FOR DEVICES, 2005-2007
TABLE 89 NUMBER OF PATENTS BY COMPANY FOR DEVICES, 2005-2007
TABLE 90 NUMBER OF PATENTS BY ASSIGNEE FOR DEVICES, 2005-2007
TABLE 91 ACRONYMS
LIST OF FIGURES
SUMMARY FIGURE WORLDWIDE REVENUE OF CARDIOVASCULAR DIAGNOSTICS, DRUGS, AND DEVICES, 2005-2012 ($ BILLIONS)
FIGURE 1 PREVALENCE OF STROKE, MYOCARDIAL INFARCTION, AND ANGINA PECTORIS BY AGE GROUP, 2005 (%)
FIGURE 2 PREVALENCE OF STROKE, MYOCARDIAL INFARCTION, AND ANGINA PECTORIS BY GENDER, 2005 (%)
FIGURE 3 PREVALENCE OF STROKE, MYOCARDIAL INFARCTION, AND ANGINA PECTORIS BY RACE/ETHINICITY, 2005 (%)
FIGURE 4 PREVALENCE OF STROKE, MYOCARDIAL INFARCTION, AND ANGINA PECTORIS BY EDUCATION 2005 (%)
FIGURE 5 PREVALENCE OF CARDIOVASCULAR DISEASES IN THE U.S., 2005 (MILLION PEOPLE)
FIGURE 6 COST OF CARDIOVASCULAR DISEASES IN THE U.S., 2005-2012 ($ BILLIONS)
FIGURE 7 MORTALITY DUE TO CARDIOVASCULAR DISEASES IN THE U.S. 2005 (%)
FIGURE 8 MORTALITY DUE TO CARDIOVASCULAR DISEASES IN THE U.S., 2005 (%)
FIGURE 9 CARDIOVASCULAR DRUGS APPROVED BY FDA, 2002-2007*
FIGURE 10 CARDIOVASCULAR DEVICES APPROVED BY THE FDA 2002-2007*
FIGURE 11 CARDIOVASCULAR DEVICES RECALLED BY FDA, 2002-2007*
FIGURE 12 MARKET SHARE OF COMPANIES PROVIDING BIOMARKER TESTS, 2006 (%)
FIGURE 13 MARKET SHARE OF COMPANIES PROVIDING POINT-OF CARE TESTING FOR CARDIAC BIOMARKERS, 2006 (%)
FIGURE 14 MARKET SHARE OF COMPANIES PROVIDING IN-VIVO DIAGNOSTICS, 2006 (%)
FIGURE 15 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-ANGINAL AGENTS, 2006 (%)
FIGURE 16 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-ARRHYTHMIC AGENTS, 2006 (%)
FIGURE 17 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-HYPERTENSIVE AGENTS, 2006 (%)
FIGURE 18 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-THROMBOTIC AGENTS, 2006 (%)
FIGURE 19 MARKET SHARE OF COMPANIES MANUFACTURING BLOOD LIPID LOWERING AGENTS, 2006 (%)
FIGURE 20 MARKET SHARE OF COMPANIES MANUFACTURING DRUGS TREATING CONGESTIVE HEART FAILURE, 2006 (%)
FIGURE 21 MARKET SHARE OF COMPANIES MANUFACTURING PACEMAKERS, 2006 (%)
FIGURE 22 MARKET SHARE OF COMPANIES MANUFACTURING CONVENTIONAL CARDIOVERTER DEFIBRILLATORS, 2006 (%)
FIGURE 23 MARKET SHARE OF COMPANIES MANUFACTURING CRTDEFIBRILLATORS, 2006 (%)
FIGURE 24 MARKET SHARE OF COMPANIES MANUFACTURING DRUG ELUTING STENTS, 2006 (%)
FIGURE 25 MARKET SHARE OF COMPANIES MANUFACTURING CATHETERS, 2006 (%)
FIGURE 26 MARKET SHARE OF COMPANIES MANUFACTURING HEART VALVES, 2006 (%)
FIGURE 27 MARKET SHARE OF COMPANIES MANUFACTURING VENTRICULAR ASSIST DEVICES, 2006 (%)
FIGURE 28 MARKET SHARE OF COMPANIES MANUFACTURING GUIDEWIRES, 2006 (%)
FIGURE 29 GLOBAL SALES OF CARDIAC BIOMARKERS, 2005-2012 ($ MILLIONS)
FIGURE 30 GLOBAL SALES OF CARDIAC BIOMARKERS, BY TYPE, 2005-2012 ($ MILLIONS)
FIGURE 31 GLOBAL SALES OF POINT-OF-CARE TESTING, 2005-2012 ($ MILLIONS)
FIGURE 32 GLOBAL SALES OF IN VIVO DIAGNOSTICS. 2005-2012 ($ MILLIONS)
FIGURE 33 WORLDWIDE MARKET SHARE OF CARDIOVASCULAR DIAGNOSTICS, 2006 (%)
FIGURE 34 GLOBAL SALES OF ANTI-ANGINAL DRUGS, 2005-2012 ($ BILLIONS)
FIGURE 35 GLOBAL SALES OF ANTI-ARRHYTHMIC DRUGS, 2005-2012 ($ BILLIONS)
FIGURE 36 GLOBAL SALES OF ANTI-HYPERTENSIVE DRUGS, 2005-2012 ($ BILLIONS)
FIGURE 37 GLOBAL SALES OF ANTI-THROMBOTIC DRUGS, 2005-2012 ($ BILLIONS)
FIGURE 38 GLOBAL SALES OF BLOOD LIPID LOWERING DRUGS, 2005-2012 ($ BILLIONS)
FIGURE 39 GLOBAL SALES OF DRUGS USED TO TREAT CONGESTIVE HEART FAILURE, 2005-2012 ($ BILLIONS)
FIGURE 40 MARKET SHARE OF CARDIOVASCULAR DRUGS, 2006 (%)
FIGURE 41 GLOBAL SALES OF PACEMAKERS, 2005-2012 ($ MILLIONS)
FIGURE 42 GLOBAL SALES OF IMPLANTABLE CARDIOVERTER DEVICES, 2005-2012 ($ MILLIONS)
FIGURE 43 GLOBAL SALES OF IMPLANTABLE CRT-DEFIBRILLATORS, 2005-2012 ($ MILLIONS)
FIGURE 44 GLOBAL SALES OF DRUG ELUTING STENTS AND GRAFTS, 2005-2012 ($ MILLIONS)
FIGURE 45 GLOBAL SALES OF CATHETERS, 2005-2012 ($ MILLIONS)
FIGURE 46 GLOBAL SALES OF HEART VALVES, THROUGH 2012 ($ MILLIONS)
FIGURE 47 GLOBAL SALES OF VENTRICULAR ASSIST DEVICES, 2005-2012 ($ MILLIONS)
FIGURE 48 GLOBAL SALES OF GUIDEWIRES, 2005-2012 ($ MILLIONS)
FIGURE 49 MARKET SHARE OF CARDIOVASCULAR DEVICES, 2006 (%)
FIGURE 50 NUMBER OF PATENTS, 2005-2007
FIGURE 51 NUMBER OF PATENTS, SHARE BY YEAR, 2005-2007 (%)
FIGURE 52 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2007
FIGURE 53 PATENTS FOR DIAGNOSTICS BY YEAR, 2005-2007
FIGURE 54 PATENTS BY COUNTRY FOR DIAGNOSTICS, 2005-2007
FIGURE 55 TOTAL NUMBER OF PATENTS BY COMPANY FOR DIAGNOSTICS, 2005-2007
FIGURE 56 NUMBER OF PATENTS BY ASSIGNEE FOR DIAGNOSTICS, 2005-2007
FIGURE 57 PATENTS BY COUNTRY FOR DRUGS, 2005-2007
FIGURE 58 TOTAL NUMBER OF PATENTS BY COMPANY FOR DRUGS, 2005-2007
FIGURE 59 NUMBER OF PATENTS BY ASSIGNEE FOR DRUGS, 2005-2007
FIGURE 60 PATENTS FOR DEVICES BY YEAR, 2005-2007
FIGURE 61 PATENTS BY COUNTRY FOR DEVICES, 2005-2007
FIGURE 62 TOTAL NUMBER OF PATENTS BY COMPANY FOR DEVICES, 2005-2007
FIGURE 63 NUMBER OF PATENTS BY ASSIGNEE FOR DEVICES, 2005-2007

For full details, please email keithw@cmsinfo.com

Top of Page

Buy now!

Single user PDF

 GBP 3031.25   

PDF Site Licence

 GBP 3718.75   

PDF Enterprise Licence

 GBP 5312.50   

Paper

 GBP 3031.25   

Your personal guarantee

Top of Page